The Evolution of RANO Criteria: Improving Accuracy in Brain Tumor Assessment
The evolution of response assessment for neuro-oncology (RANO) has allowed for development of refined criterion with the goal of increasing accuracy in the longitudinal assessment of brain neoplasms.
Subspecialty reads including RANO-HGG (high-grade glioma), iRANO (immunotherapy RANO) and RANO-BM (brain metastases) have become increasingly utilized in evaluating treatment response in their respective clinical settings. These criteria have helped address some of the response assessment challenges in the clinical trial setting in this patient population, especially with the continued development of novel therapeutic agents.
Join Dr. Pareen Mehta as he discusses:
Dr. Mehta is a board-certified, fellowship-trained neuroradiologist and nuclear medicine specialist. He has expertise in clinical trial design, clinical trial performance and clinical trial reads. In his clinical practice, Dr. Mehta serves as the medical director for the radiology department at the Angeles Clinic & Research Institute, a Cedars-Sinai affiliate. His clinical interests include brain tumors, neurodegenerative diseases and emerging radionuclide therapeutics. He has published several articles in peer-reviewed journals and serves on the editorial board of a few select journals. Outside of imaging, his hobbies include watching sports, traveling and going to the beach.